Affinity Asset Advisors LLC Makes New Investment in OnKure Therapeutics, Inc. $OKUR

Affinity Asset Advisors LLC acquired a new position in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) in the first quarter, HoldingsChannel.com reports. The firm acquired 240,963 shares of the company’s stock, valued at approximately $998,000.

Other hedge funds also recently modified their holdings of the company. ADAR1 Capital Management LLC acquired a new stake in shares of OnKure Therapeutics in the fourth quarter valued at about $2,941,000. Shay Capital LLC boosted its position in OnKure Therapeutics by 17.4% during the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock valued at $2,524,000 after purchasing an additional 135,888 shares during the last quarter. Prosight Management LP grew its stake in OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock valued at $2,369,000 after purchasing an additional 548,950 shares in the last quarter. Rosalind Advisors Inc. bought a new position in OnKure Therapeutics in the fourth quarter valued at approximately $2,118,000. Finally, Renaissance Technologies LLC increased its position in shares of OnKure Therapeutics by 40.7% during the 4th quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock worth $717,000 after purchasing an additional 71,600 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on OKUR shares. JonesTrading cut OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded shares of OnKure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, HC Wainwright dropped their price target on shares of OnKure Therapeutics to $21.00 and set a “buy” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $21.00.

OnKure Therapeutics Stock Performance

Shares of OnKure Therapeutics stock opened at $4.12 on Friday. The firm has a 50-day moving average of $4.23 and a 200-day moving average of $3.76. The stock has a market cap of $166.45 million, a PE ratio of -0.95 and a beta of 0.27. OnKure Therapeutics, Inc. has a 52-week low of $1.91 and a 52-week high of $5.38.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.37). Equities research analysts predict that OnKure Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.